



**NEVADA
HEALTH
RESPONSE**

FOR IMMEDIATE RELEASE

January 29, 2021

Meghin Delaney

Communications Director

CONTACT: pressroom@nvhealthresponse.nv.gov

COVID-19 Press Bulletin for 1-29-2021

Carson City, NV — Today, Caleb Cage, Nevada COVID-19 Response Director was joined by Candice McDaniel, Health Bureau Chief for the Bureau of Child, Family, and Community Wellness, to provide updates on Nevada's ongoing COVID-19 response, testing, and reporting during a teleconference with members of the media.

This bulletin provides facts, figures, and informational items from the call. As a reminder, data is provided in a dashboard on the home page of the [Nevada Health Response](#) website and can be accessed 24 hours a day.

SUMMARY:

- As of today, Nevada has logged 276,279 cases, with the 14-day rolling average of daily cases being 1,055.
- The state has completed a total of 2,468,681 molecular tests since the beginning of COVID-19.
- The test positivity rate over the last 14 days is 18%.
- The Nevada Hospital Associate reports there are currently 1,290 COVID-19 hospitalizations (1,189 confirmed; 101 suspected)

- More information on hospitalization trends can be found on the [Nevada Hospital Association](#) website.
- As of January 28th, 224,180 doses of COVID-19 vaccine have been administered and reported to NV WebIZ.
- There continues to be a delay in doses administered input into the data system that is being address.
- The COVID-19 vaccine is available by the federal government at no cost to the individual receiving the vaccine, but your insurance company may be billed for an administration fee.
- Individuals will not be asked to pay when receiving the vaccine, but, if you have insurance, that information may be collected.
- Nevadans are encouraged to be cautious of scams and only provide personal information to the county health department or health care providers when you make an appointment.
- A vaccine from Johnson & Johnson is being developed and that state is watching this process closely as phase 3 clinical trial data is published and an eventual submission for emergency use authorization through the Food and Drug Administration.
- This vaccine will follow the same federal review process as the Pfizer and Moderna vaccines and if it is deemed safe and effective it will be authorized for use.

###